<DOC>
	<DOCNO>NCT02971358</DOCNO>
	<brief_summary>Prostate cancer common non-skin cancer diagnose among men second lead cause male cancer death United States . In 2013 , estimate 29,270 men die prostate cancer . Although radiation surgery quite effective localized disease , effective cure men present metastatic prostate cancer 5-year relative survival rate 28 % . Currently , androgen deprivation therapy ( ADT ) via medical surgical castration standard first-line therapy men metastatic disease castration-recurrent prostate cancer ( CRPC ) eventually emerge median time 18-24 month . Once CRPC develops , secondary hormonal manipulation , chemotherapy , immunotherapy marginally effective . Given dismal prognosis metastatic prostate cancer , new idea novel approach must explore improve clinical outcome . In regard , recently emerge data suggest local tumor control may enhance effectiveness subsequent systemic therapy . Therefore , proposal , investigator design Phase I/II study prospectively evaluate safety feasibility cytoreductive prostatectomy men newly diagnose mPCa .</brief_summary>
	<brief_title>Safety Early Efficacy Radical Prostatectomy Newly Diagnosed Very High Risk Locally Advanced Oligometastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Adenocarcinoma prostate Very high risk PCA ( PSA ≥ 20 oder Gleason Score ≥ 8 oder ≥ cT3 ) and/or oligometastasierte PCA ( T N positive M , oder T N M positive ) ≤5 bone metastasis ≤75 year Ability inform consent Clinically infiltration rectum pelvic wall Clinically visceral metastasis Male , &gt; 18 Jahre Fit surgery ECOG Performance Status 0 oder 1 Male , &lt; 18 Jahre &gt; 5 bone metastasis &gt; 75 year No ability inform consent Clinically infiltration rectum pelvic wall Not fit surgery Clinically visceral metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>